Patients with HBeAg-positive chronic hepatitis B (CHB) with a maintained virological response to entecavir achieved HBsAg clearance when switched to peginterferon alfa-2a therapy (the OSST study)
Q. Ning1; M. Han1; Y. Sun2; J. Jiang3; D. Tan4; J. Hou5; H. Tang6; J. Sheng7; M. Jiang8
1. Tongji Hospital, Tongji Medical School, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
2. Tangdu Hospital, the Fourth Military Medical University, Xi'an , Shaanxi Province, China.
3. The First Hospital, Fujian Medical University, Fuzhou, Fujian Province, China.
4. Xiangya Hospital, Central South University, Changsha , Hunan Province, China.
5. Nanfang Hospital, Nanfang Medical University, Guangzhou, Guangdong Province, China.
6. Huaxi Hospital, Sichuan University, Chengdu , Sichuan Province, China.
7. The First hospital, Zhejiang University, Hangzhou , Zhejiang Province, China.
8. Shanghai Roche Pharmaceutical Co Ltd, Shanghai, China.
Study purpose: In CHB, nucleos(t)ide analog therapy can result in HBV DNA suppression, but it is difficult to achieve complete serological response and relapse occurs frequently when therapy is stopped. The phase IV Optimizing HBeAg/HBsAg Seroclearance in HBeAg-positive CHB patients with combination and Sequential Treatment of pegylated interferon alpha-2a and entecavir (OSST) study determined whether patients who had maintained HBV DNA suppression with entecavir (ETV) could achieve HBsAg clearance by switching to peginterferon alfa-2a (PEGASYS; PEG-IFN?-2a).
Methods: In the multicenter, randomized, open-label study, HBeAg-positive patients treated with ETV (0.5mg QD) for 1